HeartBeam Reports 2025 Financial Results and Advances Commercialization Following FDA Clearance

HeartBeam Inc. (NASDAQ: BEAT) reported financial and operational results for the fourth quarter and full year ended December 31, 2025, highlighting significant progress toward commercialization following U.S. Food and Drug Administration 510(k) clearance of its 12-lead electrocardiogram synthesis software in December 2025. The company has initiated a limited market launch targeting concierge and preventive cardiology groups and secured its first commercial partnership with ClearCardio. This partnership represents a crucial step in bringing the company's technology to clinical practice and expanding its market presence.

The company is also enrolling initial patients in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. This clinical development work is essential for demonstrating the system's effectiveness in real-world settings and potentially expanding its clinical applications beyond the currently cleared indications. Additional technological developments include completion of a prototype extended-wear 12-lead ECG patch, which could significantly enhance patient monitoring capabilities by allowing continuous cardiac assessment outside clinical settings.

HeartBeam has established a strategic collaboration with the Icahn School of Medicine at Mount Sinai to advance AI-enabled ECG algorithms. This partnership leverages academic expertise to enhance the company's technology platform and develop more sophisticated cardiac assessment tools. The company has also appointed a new chief commercial officer to support growth initiatives as it transitions from development to commercialization phase. These strategic moves position the company to capitalize on the FDA clearance and expand its market reach.

The HeartBeam System represents a significant advancement in cardiac monitoring technology as the first cable-free device capable of collecting ECG signals in three dimensions from three non-coplanar directions and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is located, potentially transforming how cardiac conditions are detected and monitored outside traditional medical facilities. The company's technology received FDA clearance for arrhythmia assessment in December 2024, followed by the 12-lead ECG synthesis software clearance in December 2025. Detailed information about the cleared indications for use is available at https://www.heartbeam.com/indications.

HeartBeam holds over 20 issued patents related to its technology enablement, providing intellectual property protection as it commercializes its innovations. The company's approach to cardiac care focuses on delivering actionable heart intelligence that enables physicians to identify cardiac health trends and acute conditions while directing patients to appropriate care outside medical facilities. This technology has the potential to improve early detection of cardiac events and enable more proactive management of heart conditions. The company's progress in 2025 demonstrates its transition from technology development to commercial implementation, with multiple initiatives underway to establish its presence in the cardiac care market.